Cargando…
Within trial comparison of survival time projections from short‐term follow‐up with long‐term follow‐up findings
AIMS: Data on long‐term treatment effects are scarce, despite the intent to use new therapies for many years and the need of patients, physicians and payers to have a better understanding of the lifetime benefits of treatments. The restricted mean or median survival time (RMST) calculated using age...
Autores principales: | Ferreira, João Pedro, Claggett, Brian L., Docherty, Kieran F., Jhund, Pardeep S., Zannad, Faiez, Solomon, Scott D., McMurray, John J.V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715817/ https://www.ncbi.nlm.nih.gov/pubmed/35799450 http://dx.doi.org/10.1002/ehf2.13731 |
Ejemplares similares
-
Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020) -
Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022) -
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020) -
Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study
por: Macpherson, Karen J, et al.
Publicado: (2011) -
Serum potassium in the PARADIGM‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)